Could half the treatment be just as good? major melanoma trial challenges One-Year standard
NCT ID NCT06488482
First seen Mar 10, 2026 · Last updated May 24, 2026 · Updated 11 times
Summary
This study compares 6 months versus 12 months of immunotherapy (nivolumab or pembrolizumab) in 1,792 people with high-risk melanoma who had surgery. The goal is to see if the shorter treatment prevents cancer from coming back just as well, while causing fewer side effects and requiring fewer hospital visits. Participants are randomly assigned to either 6 or 12 months of treatment and followed for up to 5 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Akershus University Hospital
RECRUITINGOslo, Norway
Contact
-
Eskilstuna Hospital
RECRUITINGEskilstuna, Sweden
Contact
-
Falu Hospital
RECRUITINGFalun, Sweden
Contact
-
Gävle Hospital
RECRUITINGGävle, Sweden
Contact
-
Haukeland University Hospital
RECRUITINGBergen, Norway
Contact
-
Helsinki University Hospital
RECRUITINGHelsinki, Finland
Contact
-
Kalmar Hospital
RECRUITINGKalmar, Sweden
Contact
-
Karlstad Hospital
RECRUITINGKarlstad, Sweden
Contact
-
Karolinska University Hospital
RECRUITINGStockholm, Sweden
Contact
-
Kuopio University Hospital
RECRUITINGKuopio, Finland
Contact
-
Linköping University Hospital
RECRUITINGLinköping, Sweden
Contact
-
North Norway University Hospital
RECRUITINGTromsø, Norway
Contact
-
Oslo University Hospital
RECRUITINGOslo, Norway
Contact
-
Ryhov Hospital
RECRUITINGJönköping, Sweden
Contact
-
Sahlgrenska University Hospital
RECRUITINGGothenburg, Sweden
Contact
-
Skåne University Hospital
RECRUITINGLund, Sweden
Contact
-
Sorlandet Hospital
RECRUITINGKristiansand, Norway
Contact
-
Stavanger University Hospital
RECRUITINGStavanger, Norway
Contact
-
Sundsvall Hospital
RECRUITINGSundsvall, Sweden
Contact
-
Tampere University Hospital
RECRUITINGTampere, Finland
Contact
-
Trondheim University Hospital
RECRUITINGTrondheim, Norway
Contact
-
Turku University Hospital
RECRUITINGTurku, Finland
Contact
-
Västmanland Hospital
RECRUITINGVästerås, Sweden
Contact
-
Växjö Hospital
RECRUITINGVaxjo, Sweden
Contact
-
Ålesund Hospital
RECRUITINGÅlesund, Norway
Contact
-
Örebro University Hospital
RECRUITINGÖrebro, Sweden
Contact
Conditions
Explore the condition pages connected to this study.